Reviewing the performance of single-payer health systems versus the United States system. Suggesting an alternative approach that offers simplification via strategic deregulation to enhance market competition.

To stop COVID-19 dead in its tracks, many governors, mayors and superintendents are threatening to keep schools closed this fall, failing to consider the greater harm that comes from refusing to open them.

Our governmental COVID-19 mitigation policy of broad societal lockdown focuses on containing the spread of the disease at all costs, instead of “flattening the curve” and preventing hospital overcrowding. Although well-intentioned, the lockdown was imposed without consideration of its consequences beyond those directly from the pandemic.

Now is the time for the design of sound public policy — and that involves a far broader formulation than a single-minded focus on stopping COVID-19 at all costs.

Generics are often made in India, with ingredients from China. Time to diversify the supply chain.

The tragedy of the COVID-19 pandemic appears to be entering the containment phase. Tens of thousands of Americans have died, and Americans are now desperate for sensible policymakers who have the courage to ignore the panic and rely on facts. Leaders must examine accumulated data to see what has actually happened, rather than keep emphasizing hypothetical projections; combine that empirical evidence with fundamental principles of biology established for decades; and then thoughtfully restore the country to function.

Mediocre U.S. rankings in infant mortality and life expectancy have little to do with health-care quality.

Cost is only part of the problem. Single-payer systems create long waits and delays on new drugs.